Lantus News and Research

RSS
Shopping abroad for cheaper medication? Here’s what you need to know

Shopping abroad for cheaper medication? Here’s what you need to know

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

T1DM therapeutics market expected to reach $7.1 billion by 2021

T1DM therapeutics market expected to reach $7.1 billion by 2021

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Degludec effectively lowers blood glucose with lower risk for hypoglycemia

Degludec effectively lowers blood glucose with lower risk for hypoglycemia

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin and Lilly terminate exenatide alliance, resolve litigation

Lantus initiation may help limit weight gain in type 2 diabetes patients

Lantus initiation may help limit weight gain in type 2 diabetes patients

First-ever comprehensive study of species origins of nature-derived drugs

First-ever comprehensive study of species origins of nature-derived drugs